Navigation Links
Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
Date:9/17/2008

desire to ensure that the study is appropriately powered to generate a data set that, if the results are positive, will establish a path forward for a pivotal trial," stated Vaughn M. Kailian, President and Chief Executive Officer of Memory Pharmaceuticals. "Enrollment in the CIAS trial has gone well, and we expect the expansion of the trial to continue on that trend. Most importantly, this announcement, coupled with the plan to commence a further trial in Alzheimer's disease later this year, underscores the collective excitement of Roche and Memory about the potential of R3487/MEM 3454 in both of these debilitating diseases."

The Phase 2 trial is in patients with stable schizophrenia who are receiving atypical antipsychotic therapy. Subjects in the study are randomized to receive 5 mg, 15 mg or 50 mg of R3487/MEM 3454 or placebo once daily for a period of eight weeks. The primary objective of the trial is to assess the effectiveness of R3487/MEM 3454 in CIAS using the MATRICS Consensus Cognitive Battery (MCCB). Secondary objectives include measures of other symptoms of schizophrenia and functional capacity.

About R3487/MEM 3454

R3487/MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a highly specialized receptor found in the central nervous system. In a recently completed Phase 2a study in Alzheimer's disease patients, R3487/MEM 3454 demonstrated a statistically significant effect on multiple measures of cognition. In May 2008, Roche exercised its option to license R3487/MEM 3454 for future development and commercialization.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at '/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Suggests a Possible Way to Offset Chemobrain Memory Loss
2. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
3. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
4. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
5. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
6. How Big Is Your Brain? Its Size May Protect You from Memory Loss
7. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
8. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
9. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
10. Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease
11. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... Scientific Corporation (NYSE: BSX ) today announced ... of Los Gatos, California.  The transaction follows the definitive ... terms of the agreement, Boston Scientific paid $193 million ... equity not already owned by Boston Scientific.  Additional payments ...
... 4, 2011 ERT (Nasdaq: ERES ), announced ... and Keith Schneck, the Company,s Chief Financial Officer, are scheduled ... at 9:30 AM PST on January 13, 2011 in San ... by visiting the Company,s corporate website at http://www.ert.com . ...
Cached Medicine Technology:Boston Scientific Completes Acquisition of Sadra Medical 2Boston Scientific Completes Acquisition of Sadra Medical 3Boston Scientific Completes Acquisition of Sadra Medical 4ERT to Present at the 29th Annual J.P. Morgan Healthcare Conference on January 13, 2011 2
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... 25, 2014 Thousands of transvaginal mesh ... in a number of multidistrict litigations currently underway in ... Liebhard LLP reports. According to an Order issued on ... a Joint Status Conference in all of the proceedings ... been directed to submit a proposed agenda to the ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Plugin ... of ProFire 5k. A fully customizable business presentation tool ... , “Adding the ProFire 5k business tool, users can ... Christina Austin, CEO of Pixel Film Studios. “ProFire 5k ... and style to add professionalism to a presentation” , ...
(Date:12/25/2014)... December 25, 2014 Each year trauma ... 2 million hospital admissions across the nation (according to ... The CDC’s National Hospital Ambulatory Medical Care Survey ... survey conducted in 2010. They estimated that there were ... resulted in a primary diagnosis of broken bone or ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping ... items. During the holiday season, AlignLife looks forward to their ... says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our ... that we are able to give kids toys for Christmas ... for the generosity of our patients." , The 70 toys ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... Newer Single-Pill Fixed Combination Brands, According to a New ... , NASHVILLE, Tenn., Dec. 10 HealthLeaders-InterStudy, ... that although Novartis, Exforge and Tekturna have slowly penetrated ... over the last 12 months, their progress has stalled. ...
... Finding Dr. Right brings together in one resource the necessary information to ... time of year , ... Lyndhurst, NJ (PRWEB) December 10, 2008 -- ... figuring out what an otolaryngologist is), navigating the medical landscape can be ...
... Mobile System to Launch in Three Skilled Nursing Facilities ... Dec. 10 After an intense 18-month selection process, ... contract to deploy electronic medical records (EMR) throughout Metropolitan ... , Metropolitan, a nationally ...
... Inc., the world,s leading manufacturer and distributor of automated blood ... Consulting, an expert in Internet software development, team-up to launch ... ... Burtonsville, MD (PRWEB) December 10, 2008 -- ...
... Phase II Cancer Trials and the Company,s Other Clinical Programs All ... - Significant Validation Achieved for Bavituximab and Peregrine,s Anti-PS Anti-Viral ... - Company Enters into Loan Agreement for Up to ... TUSTIN, Calif., Dec. 10 Peregrine Pharmaceuticals, Inc. (Nasdaq: ...
... Dec. 10 Michael Merzenich, PhD, a leading ... the Chief Scientist of Posit Science Corporation, gave ... of a joint conference of the Netherlands Institute ... Arts and Science in Amsterdam. His talk, ...
Cached Medicine News:Health News:Downgraded Tier Positions and Step Therapy Restrictions Have Stalled Exforge's and Tekturna's Growth in The Hypertension Drug Market 2Health News:Downgraded Tier Positions and Step Therapy Restrictions Have Stalled Exforge's and Tekturna's Growth in The Hypertension Drug Market 3Health News:Vitals Launches Free eBook to Help Consumers Find "Dr. Right" 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 3Health News:Lifeclinic International and Get Real Consulting Team-Up to Launch Microsoft's HealthVault 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 3Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 4Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 5Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 6Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 7Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 8Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 9Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 10Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 11Health News:Posit Science Co-Founder and Brain Plasticity Pioneer, Michael Merzenich, Speaks at Science Conference in the Netherlands 2
... Stand Magnifier offers versatility across a ... lens and the light are adjustable. ... hand held objects can be worked ... parallel to the work surface, lay ...
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
... Piston assembly fits into neck of platform ... ready position after use. Cutting block fits ... disposable trephine blades sized 6.25 - 9.0 ... the preparation of corneal donor buttons for ...
... allows the surgeon to effectively ... scrub-resistant, gentian violet ink. All ... sterile, with a ruler and ... pouches. Micro tip marker for ...
Medicine Products: